Clinical Trials Directory

Trials / Unknown

UnknownNCT05259020

To Evaluate the Pharmacokinetics and the Safety of ID14009 Compared to Coadministration of ID1805 With ID1803 in Healthy Adult Volunteers

An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Cross-over, Clinical Trial to Evaluate the Pharmacokinetics and the Safety of ID14009 Compared to Coadministration of ID1805 With ID1803 in Healthy Adult Volunteers.

Status
Unknown
Phase
Phase 1
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
IlDong Pharmaceutical Co Ltd · Industry
Sex
All
Age
19 Years
Healthy volunteers
Accepted

Summary

To evaluate the pharmacokinetics and the safety of ID14009 compared to coadministration of ID1805 with ID1803 in healthy adult volunteers.

Conditions

Interventions

TypeNameDescription
COMBINATION_PRODUCTID140009Combination Product: ID140009 Ezetibmibe 10mg/ Rosuvastatin Ca 20.8mg/ Amlodipine 10mg/ Valsartan 160mg
COMBINATION_PRODUCTID1803+ID1805(Amlodipine 10mg/Valsartan 160mg)+(Ezetibmibe 10mg/ Rosuvastatin Ca 20.8mg)

Timeline

Start date
2022-02-22
Primary completion
2022-03-30
Completion
2022-03-30
First posted
2022-02-28
Last updated
2022-02-28

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT05259020. Inclusion in this directory is not an endorsement.

To Evaluate the Pharmacokinetics and the Safety of ID14009 Compared to Coadministration of ID1805 With ID1803 in Healthy (NCT05259020) · Clinical Trials Directory